NuSirt Biopharma, Inc. has developed a breakthrough technology platform that combines natural compounds with various pharmaceutical agents.

The company has protected the discovery and application of this broad based technology platform through an extensive IP portfolio that includes thirteen issued or allowed to date with corresponding patents pending globally. NuSirt has successfully conducted multiple clinical studies that have validated its discovery and demonstrated the value of its intellectual property.

Learn More

Call 615-810-8191

Or Request more information.

NuSirt News

NS-WM-01 enrollment completed


11th Annual Diabetes Summit, April 10-11, Boston, MA

Joe Cook, Jr. to present in the  “Funding and Commercialization” Session

Michael Zemel, PhD to present, “Clinical Utility of Energy-Sensing Targets for Diabetes & Metabolic Syndrome” in the “What’s New in Type 2 Diabetes Session”


EASL abstract accepted, presentation date, April 12, 2018 Paris, France



See All News


3835 Cleghorn Avenue, Suite 200
Nashville, TN 37215